PMS Registry
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
Company Name
Title of Study
Update Date
Pfizer TRANSTHYRETIN-ASSOCIATED AMYLOIDOSIS OUTCOMES SURVEY (THAOS): A GLOBAL, MULTI-CENTER, LONGITUDINAL, OBSERVATIONAL SURVEY OF PATIENTS WITH DOCUMENTED TRANSTHYRETIN (TTR) MUTATIONS OR WILD-TYPE TTR AMYLOIDOSIS 2019-02-11
Pfizer Thromboembolic and Bleeding Risks of Apixaban, Rivaroxaban and Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation 2019-02-11
Pfizer Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan, A Retrospective NHIA Database Analysis 2019-02-11
Bayer Taiwan Co., Ltd. AURIGA / An observationAl stUdy pRogram to InvestiGate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting. 2019-02-11
Pfizer Treatment Patterns And Clinical Outcomes Among Taiwanese Patients Receiving Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. 2019-02-11
Pfizer The Observational Registry: Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients 2019-02-11
Daiichi Sankyo Taiwan Ltd. Phase IV, non-comparative, open label, multicenter, 28-week switching study of prasugrel maintenance dose from clopidogrel in patients with acute coronary syndrome (ACS) who underwent a percutaneous coronary intervention (PCI) in Taiwan 2019-02-11
Bayer Taiwan Co., Ltd. TAURUS: A MulTinational PhAse IV Study EvalUating “Real World” Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog alfa) for RoUtine ProphylaxiS. 2019-02-11
Bayer Taiwan Co., Ltd. REFINE: Regorafenib observational study in hepatocellular carcinoma 2019-02-11
AbbVie Biopharmaceuticals GmbH Taiwan Branch A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST) 2019-02-11
   1 2 3 4 5